Exscientia Announces Second Molecule Created Using AI From Sumitomo Dainippon Pharma Collaboration to Enter Phase 1 Clinical Trial
13.5.2021 10:30:00 EEST | Business Wire | Press release
Exscientia Ltd. (Headquarters: Oxford, UK; CEO: Andrew Hopkins) is pleased to acknowledge that Sumitomo Dainippon Pharma Co., Ltd. (Head office: Osaka, Japan, Representative Director, President and CEO: Hiroshi Nomura) has announced that they will initiate a Phase 1 clinical study of DSP-0038 in the United States for the treatment of Alzheimer’s disease psychosis.
DSP-0038 is the third molecule created using Exscientia’s Artificial Intelligence (AI) technologies to enter clinical trials. The two earlier compounds are DSP-1181, announced in 2020 together with Sumitomo Dainippon Pharma to treat obsessive-compulsive disorder, and Exscientia’s immuno-oncology agent, EXS-21546, announced earlier this year.
Joint research between Exscientia and Sumitomo Dainippon Pharma designed DSP-0038 to be a single small molecule that exhibits high potency as an antagonist for the 5-HT2A receptor and agonist for the 5-HT1A receptor, whilst selectively avoiding similar receptors and unwanted targets, such as the dopamine D2 receptor. Selective dual targeting is a major challenge for conventional drug discovery, and psychiatric indications also require exceptional selectivity to avoid off-target effects. The successful design of DSP-0038 demonstrates opportunities to design selective molecules with dual activity.
DSP-0038 will be assessed for improved antipsychotic effects associated with Alzheimer’s disease psychosis, as well as improvements in behavioural and psychological symptoms of dementia which include agitation, aggression, anxiety, and depression.
Toru Kimura, Representative Director, Executive Vice President and Chief Scientific Officer of Sumitomo Dainippon Pharma, said: "We have been impressed by the outstanding productivity of Exscientia's AI technologies. The combination of Exscientia’s AI with our company’s deep experience in monoamine GPCR drug discovery has now led to two molecules reaching our clinical pipeline from this collaboration.”
Andrew Hopkins, CEO of Exscientia, said: "This is further validation that our AI platform can turn complex biological challenges into high-quality clinical candidates quickly. To have what we believe to be the world’s first three clinical molecules created using AI arising from our own platform – two with Sumitomo Dainippon Pharma - is a wonderful achievement. We hope that through the creation of DSP-0038 improved treatments for Alzheimer’s disease psychosis will be realized."
About Exscientia
Exscientia is an AI-driven pharmatech company committed to discovering and designing the best possible medicines in the fastest and most effective manner. Exscientia is the first company to progress AI-designed small molecules into the clinical setting and repeatedly demonstrate the ability of AI to transform how drugs are created. Exscientia’s AI platform has now designed two drugs that are in Phase 1 human clinical trials.
Drug design is precision engineering at the molecular scale. Exscientia has built dedicated AI systems that efficiently learn from the widest range of data and consistently reapply enhanced knowledge through iterations of design. Because Exscientia’s AI platform learns more effectively and rapidly than human-led efforts alone, candidate molecules satisfying complex therapeutic requirements are created with revolutionary efficiency. Exscientia believes that designing better drugs, faster, will allow the best ideas of science to rapidly become the best medicines for patients.
Exscientia has offices in Oxford, Miami, Osaka and Dundee. For more information visit us on www.exscientia.ai or follow us on Twitter @exscientiaAI.
About Sumitomo Dainippon Pharma Co., Ltd.
Sumitomo Dainippon Pharma defines its corporate mission as "To broadly contribute to society through value creation based on innovative research and development activities for the betterment of healthcare and fuller lives of people worldwide." By pouring all our efforts into the research and development of new drugs, we aim to realize our corporate mission and provide innovative and effective pharmaceutical
solutions to people not only in Japan but also around the world. Sumitomo Dainippon Pharma's goal is to create innovative pharmaceutical products in the focus research areas of Psychiatry & Neurology, Oncology and Regenerative Medicine/Cell Therapy. For further details, visit https://www.ds-pharma.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210513005059/en/
Contact information
Enquiries:
Edelman
Anitra Sprauten
P: +44 (0)7896 859386
Anitra.Sprauten@edelman.com
Stephanie Crisp
P: +44 (0)7583 003417
Stephanie.Crisp@edelman.com
For Exscientia
Mark Swindells: contact@exscientia.ai
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
REPLY Unveils the New Editions of the Reply AI Music Contest and Reply AI Film Festival under the Theme “Imaginatio Nova”19.3.2026 10:00:00 EET | Press release
Reply [EXM, STAR: REY, ISIN: IT0005282865] confirms its commitment for 2026 to fostering dialogue between creativity, technology and artificial intelligence through the Reply AI Music Contest and the Reply AI Film Festival, the two international AI competitions open to creatives, filmmakers, musicians and innovation professionals from around the world. The theme of the 2026 edition, “Imaginatio Nova”, is an invitation to explore a new phase of imagination, where human creativity is renewed through technology. This approach views artificial intelligence not as a substitute for artistic talent, but as a catalyst for new visions, languages and expressive possibilities, capable of generating forms that did not previously exist. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260319315132/en/ These initiatives are part of the Reply Challenges, a programme of technological and creative competitions that reflects Reply’s commitment
Valeo Foods Group Accelerates Growth in Eastern Europe With Acquisition of Prestige-96, a Leading Bulgarian Sweet Baked Goods Player19.3.2026 09:00:00 EET | Press release
Valeo Foods Group, one of Europe’s leading producers of sweets, treats and snacks, today announced that it has reached an agreement to acquire 100% of Prestige-96 AD (“Prestige”), a market-leading Bulgarian manufacturer of sweet baked goods. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260319225232/en/ Prestige-96 sandwich biscuits. Founded in 1996, Prestige is one of Bulgaria’s most established and trusted producers of biscuits, wafers and sweet snack products. Its portfolio features some of the country’s most recognisable local brands including - Naya (Ная), Hyper (Хайпър), Mirage (Мираж) and Roden Kray (Роден Край). Prestige employs approximately 450 people across its operations. The acquisition marks a significant milestone in Valeo Foods Group’s long-term growth strategy, focused on acquiring market-leading, iconic local brands as part of its continued European expansion. As Valeo Foods Group’s eighth acquisition sinc
SymphonyAI AI Platforms Deployed for Compliance Environment at Munich Re19.3.2026 08:32:00 EET | Press release
As regulatory expectations grow more complex and financial crime risks continue to evolve, SymphonyAI, a global leader in Vertical AI platforms, offers a centralized, enterprise-grade technology foundation designed to operate at global scale while meeting local regulatory requirements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260319144999/en/ SymphonyAI supports Munich Re, one of the leading reinsurers, and subsidiaries through its financial crime platform, which combines domain-specific expertise with artificial intelligence to help financial institutions detect, investigate, and manage financial crime risk with greater precision and efficiency. “Integrated, production-scale financial crime platforms that can evolve with the risk landscape,” said John Edison, President of Financial Services, SymphonyAI. “Our work together with Munich Re reflects a shared focus on flexibility, performance, and long-term modernization,
Royal Moroccan Football Federation Acknowledges Decision Rendered by the CAF Appeals Committee18.3.2026 19:49:00 EET | Press release
The Royal Moroccan Football Federation (FRMF) wishes to reiterate that its appeal was never aimed at contesting the sporting merit or performance of the teams involved in this tournament, but solely to ensure the proper enforcement of competition regulations. The federation reaffirms its commitment to respecting the regulations, ensuring the clarity of the competitive framework and maintaining the stability of African football competitions. The Federation also wishes to commend all the nations that participated in this year’s edition of the Africa Cup of Nations (AFCON), which served as a significant moment for African football. The FRMF will issue a more comprehensive official statement in the coming days after a scheduled meeting of its governing bodies. Source: AETOSWire View source version on businesswire.com: https://www.businesswire.com/news/home/20260318763307/en/
SIMCON Unveils World’s First Large Engineering Model for Plastic Injection Moulding18.3.2026 19:05:00 EET | Press release
SIMCON today announced the launch of the Cadmould AI Solver, the world’s first Large Engineering Model for injection moulding. Co-developed with Emmi AI, the new transformer-based architecture delivers simulation results up to 1000 times faster than traditional numerical solvers. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260318680159/en/ SIMCON’s new Cadmould AI Solver delivers injection molding simulation results in seconds. By removing lengthy computation times, the tool enables engineers to dynamically explore thousands of design and process variations in a single day. Historically, lengthy computation times have acted as a bottleneck, limiting the number of design variations engineers can practically explore during the development process. The Cadmould AI Solver shatters this barrier by providing engineers with instant feedback on filling pattern, pressure, and temperature in seconds. What once required hours per si
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom